Research Options: Select below IPO Calendar	Week of Expected Pricing Pending Company Name ACTUATE THERAPEUTICS, INC. Proposed Ticker ACTU CUSIP N/A Business Description We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3ß, a master regulator of complex biological signaling cascades, including those mediated by oncogenes,that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade of GSK-3ß signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. Lead Underwriter Titan Partners Group LLC, a division of American Capital Part... Co-Managers Newbridge Securities Corporation Initial Shares N/A Revised Initial Shares N/A Initial Price N/A Revised Price N/A Final Price N/A Final Ticker N/A
	© 2024 ICE Data Services. All rights reserved.